scispace - formally typeset
L

Lewis L. Lanier

Researcher at University of California, San Francisco

Publications -  576
Citations -  93495

Lewis L. Lanier is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Interleukin 21 & Natural killer cell. The author has an hindex of 159, co-authored 554 publications receiving 86677 citations. Previous affiliations of Lewis L. Lanier include University of Rome Tor Vergata & Cancer Research Institute.

Papers
More filters
Patent

B70(b7-2):ctla-4 bonding protein

TL;DR: B70 antigen from a mammal, and reagents relating thereto, including purified nucleic acids encoding such proteins, proteins, and specific antibodies, are provided, together with methods of using said reagents and diagnostic kits using such reagents as mentioned in this paper.
Journal ArticleDOI

Recognition of host Clr-b by the inhibitory NKR-P1B receptor provides a basis for missing-self recognition.

TL;DR: The authors solve the structure of an NK inhibitory receptor, NKR-P1B, bound to its ligand, Clr-b, with further data suggesting a weak interaction and informing on the basis of missing-self recognition, and suggest an avidity-based mechanism underpins N KR-P 1B receptor function.
Journal ArticleDOI

Cutting Edge: NKG2D Signaling Enhances NK Cell Responses but Alone Is Insufficient To Drive Expansion during Mouse Cytomegalovirus Infection.

TL;DR: It is demonstrated that NKG2D augments Ly49H-dependent proliferation of NK cells; however, NKG1D signaling alone is inadequate for expansion ofNK cells, likely due to only transient expression of the NKG 2D–DAP12 complex.
Journal ArticleDOI

KLRE/I1 and KLRE/I2: A Novel Pair of Heterodimeric Receptors That Inversely Regulate NK Cell Cytotoxicity

TL;DR: It is demonstrated that KLRE1 forms functional heterodimers with either KLRI1 or KLRI2, demonstrating that KLre/I1 is a functional inhibitory heterodimer in NK cells, whereas KLRE/I2 is an activating heterodimmeric receptor.